Trial Profile
A Randomized, Double Blind, Placebo-controlled, Multicenter, Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Registrational; Therapeutic Use
- Acronyms ReTHINK
- Sponsors Novartis; Novartis Pharmaceuticals
- 08 Jul 2019 Status changed from completed to discontinued.
- 30 Jun 2019 This trial has been discontinued in UK.
- 11 Jan 2018 Status changed to completed.